Bridging the Gap: How Fractional CMOs Propel Biotech Success

Bridging the Gap: How Fractional CMOs Propel Biotech Success In the dynamic and high-stakes world of biotechnology, early-stage companies navigate a complex landscape of scientific innovation,...
Learn More

EMA Policy 0070: A New Era of Transparency in EU Regulatory Affairs

EMA Policy 0070: A New Era of Transparency in EU Regulatory Affairs The European Medicines Agency (EMA) has ushered in a new era of transparency with the reinstatement of Policy 0070 in late 2023....
Learn More

The Hidden Pitfalls of Unconscious Bias in Drug Development

Please be assured this is not a woke rant dealing with micro-aggressions or cultural stereotyping, but about something potentially much more impactful on drug development outcomes. It deals with the...
Learn More

The Perils of Misaligned Incentives: Why Drugs Fail Late in Development

Intro The journey of a drug from conception to market is notoriously fraught with challenges. In the high-stakes world of biotech and pharmaceutical development, it can be particularly damaging to...
Learn More

Maybe they should start calling it Decelerated Approval?

The FDA is proposing that a single trial could support both accelerated and full approval of oncology therapeutics. At first glance this seems to be a promising development. Though, as one reads more...
Learn More

Could COVID-19 be a catalyst for virtualizing clinical trials?

The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
Learn More

Summer in Paris: NASH Update

Title: Summer in Paris: NASH Update Author: Peter G. Traber, MD Date: 07/16/2019 The Paris NASH meeting was held July 11 and 12, 2019, subtitled as an “International Think Tank” and it certainly did...
Learn More

Therapy for NASH Cirrhosis is a Distant Hope

NASH is a chronic liver disorder that results in progressive fibrosis, ultimately culminating in some patients in liver cirrhosis. In cirrhosis, the fibrotic scar tissue distorts the normal liver...
Learn More

NASH Surprises and Interpretation of Clinical Trials

Title: NASH Surprises and Interpretation of Clinical Trials Author: Peter G. Traber, MD Introduction 2019 will usher in a new chapter in NASH drug development with data reported on the first phase 3...
Learn More

Industry Strategies for NASH Combination Therapies

Introduction: Many have commented that drug combinations represent the future of NASH therapeutics. As indicated by Pfizer’s recent announcement, large pharma companies are putting efforts toward the...
Learn More

Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.